Radiopharm Theranostics Reports 93% Concordance in Phase 2b Trial of RAD101 for Brain Metastases Detection

RAD101 Meets Primary Endpoint in Multicenter Phase 2b Diagnostic Study

Radiopharm Theranostics announced that RAD101 demonstrated robust diagnostic accuracy in its U.S. Phase 2b clinical trial, fulfilling the primary endpoint of concordance between PET imaging and MRI results. The study included all 30 evaluable patients in a multicenter, open-label, single-arm trial assessing RAD101's ability to detect suspected recurrent brain metastases after prior radiotherapy. The trial reported 93% concordance between 18F-RAD101 PET-positive lesions and equivocal findings on contrast-enhanced MRI, highlighting significant and selective tumor uptake of the imaging agent.

RAD101 is a novel small molecule imaging agent that selectively targets fatty acid synthase (FASN), a protein overexpressed in brain metastases from solid tumors. This mechanism enables more precise detection of cancer cells within the central nervous system compared to conventional imaging techniques. The trial specifically evaluated RAD101's capacity to differentiate recurrent disease from treatment effects in patients previously treated with stereotactic radiosurgery (SRS), addressing a critical diagnostic challenge in neuro-oncology where MRI has limitations in follow-up surveillance.

Secondary Sensitivity Data Reinforce RAD101's Potential in Brain Cancer Imaging

Further analysis of Phase 2b data showed a preliminary sensitivity of 86% in 14 patients with evaluable six-month follow-up and biopsy data, equating to 12 out of 14 patients. Sensitivity measures the test’s ability to correctly identify patients with disease, and this promising result supports RAD101's diagnostic effectiveness. Specificity data, which assesses correct identification of patients without disease, is expected in Q4 2026 to complete secondary endpoint evaluation.

These preliminary sensitivity outcomes are particularly important given the clinical context of brain metastases diagnosis. RAD101 provided metabolic activity insights via PET imaging that clarified equivocal MRI findings, addressing a significant clinical need in post-radiotherapy monitoring. This capability may enable clinicians to better distinguish between recurrent tumor growth and radiation-induced tissue changes, facilitating more accurate patient management and treatment decisions. The strength of these findings underpins the advancement of RAD101 into a registrational Phase 3 program.

Brain Metastases Imaging Market Opportunity Surpasses $600 Million

The brain metastases imaging market represents a substantial opportunity for RAD101, valued at over $600 million. In the U.S. alone, more than 300,000 patients are diagnosed annually with cerebral metastases, a figure rising partly due to improved systemic therapies yielding longer tumor control outside the central nervous system. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) remains the standard for intracranial metastatic disease detection but has recognized limitations, especially in follow-up surveillance that affects optimal patient care.

Importantly, no PET imaging product is currently approved specifically for diagnosing brain metastases in this population, highlighting a significant unmet medical need. RAD101 aims to fill this gap by offering a more precise diagnostic tool that provides metabolic information complementary to MRI. The increasing incidence of cerebral metastases, combined with existing imaging limitations and absence of approved PET options, creates a compelling commercial opportunity for RAD101. This market dynamic emphasizes the potential impact of RAD101's clinical progress.

FDA Fast Track Designation Expedites RAD101's Regulatory Pathway

RAD101 has been granted U.S. Food and Drug Administration Fast Track Designation, a regulatory status for drugs treating serious conditions with potential to address unmet medical needs. This designation supports RAD101’s ability to differentiate recurrent brain metastases from treatment effects originating from various solid tumors, including leptomeningeal disease. Fast Track status facilitates more frequent FDA interactions during development and may accelerate review of regulatory submissions, aiding Radiopharm’s goal of delivering RAD101 to patients more efficiently.

The FDA’s Fast Track recognition underscores the significant clinical challenge RAD101 addresses and the promise of its therapeutic approach. This is especially critical in brain metastases diagnosis, where diagnostic inaccuracies can lead to unnecessary retreatment or missed recurrence, impacting patient outcomes and quality of life. The designation enables Radiopharm to maintain ongoing dialogue with the FDA as it finalizes Phase 3 trial design, ensuring alignment on clinical endpoints and regulatory requirements vital for marketing approval.

Siemens Healthineers Partnership Bolsters Phase 3 Trial Manufacturing and Distribution

Radiopharm Theranostics recently formed a strategic partnership with Siemens Healthineers, a global medical technology leader, to manufacture and distribute 18F-labeled RAD101 doses for the upcoming U.S. Phase 3 pivotal trial. This agreement addresses critical operational needs for late-stage clinical development, as the radioactive imaging agent requires specialized production and logistics to maintain quality, stability, and timely delivery across multiple trial centers.

Collaborating with an established manufacturer like Siemens Healthineers demonstrates confidence in RAD101’s clinical promise and grants Radiopharm access to Siemens’ extensive infrastructure and expertise in radiopharmaceutical production and distribution. This partnership is vital for a multicenter global Phase 3 trial demanding consistent supply of the imaging agent to numerous hospitals and imaging facilities. Securing manufacturing support ahead of Phase 3 allows Radiopharm to focus on trial execution without logistical delays.

Phase 3 Pivotal Trial Scheduled for Q4 2026

Radiopharm Theranostics intends to commence a U.S. Phase 3 pivotal trial for RAD101 in Q4 2026, building on encouraging Phase 2b results and FDA guidance. The company is finalizing trial design through ongoing FDA discussions to ensure regulatory compliance for a registrational study. This timeline indicates a swift transition from Phase 2b data analysis to pivotal trial initiation, which will provide the primary evidence for regulatory approval and commercialization.

Advancing to Phase 3 marks a key milestone in RAD101’s development. Phase 3 studies typically involve larger, multicenter, randomized or comparative designs to generate robust data required for regulatory clearance. For RAD101, the Phase 3 program will likely validate sensitivity and specificity in a broader patient cohort across multiple sites to demonstrate reproducibility and clinical utility. Success would position RAD101 for FDA approval and market entry in a space currently without approved PET imaging alternatives.

RAD101 Targets Fatty Acid Synthase Overexpression in Brain Tumors

RAD101 is a novel small molecule imaging agent that selectively binds to fatty acid synthase (FASN), an enzyme complex responsible for de-novo fatty acid synthesis and notably overexpressed in cerebral metastases from solid tumors. Targeting FASN is based on the observation that cancer cells in the CNS often increase fatty acid synthesis to support rapid growth. By labeling the FASN-binding molecule with Fluorine-18, a positron-emitting isotope used in PET scans, RAD101 enables visualization of FASN expression levels, highlighting metabolically active tumor cells.

This approach advances neuro-oncology imaging by providing metabolic data that complements structural MRI findings. Positive Phase 2a imaging results from Imperial College London showed significant tumor uptake of 18F-RAD101 regardless of tumor origin, confirming the FASN-targeting strategy’s applicability across brain metastases from lung, breast, and other solid tumors. This broad utility is clinically valuable, as brain metastases arise from diverse cancers, and a universal diagnostic agent offers enhanced clinical relevance compared to tumor-specific alternatives.

Radiopharm Theranostics’ Expansive Pipeline Extends Beyond Brain Metastases

Radiopharm Theranostics is a clinical-stage radiopharmaceutical company developing a portfolio of innovative diagnostic and therapeutic agents addressing high unmet medical needs. Listed on the ASX (RAD) and NASDAQ (RADX), the company accesses both Australian and global capital markets. Beyond RAD101, Radiopharm’s pipeline includes one Phase 2b and five Phase 1 trials targeting various solid tumors such as lung, breast, and brain metastases, reflecting a diversified oncology radiopharmaceutical development strategy.

The company’s platform incorporates distinct technologies using peptides, small molecules, and monoclonal antibodies for cancer imaging and treatment. This multi-modality approach enables Radiopharm to tackle different facets of cancer diagnosis and therapy, potentially generating synergies across programs while building expertise in manufacturing, regulatory processes, and commercialization. The broad pipeline offers multiple clinical and commercial opportunities, reducing reliance on any single program for long-term growth.

Imperial College London Phase 2a Data Validates RAD101’s Mechanism and Clinical Value

Earlier imaging data from Imperial College London’s Phase 2a trial of 18F-RAD101 in patients with brain metastases—including both SRS-treated and treatment-naïve individuals—demonstrated significant tumor uptake independent of tumor origin. This validates the FASN-targeting mechanism across diverse cancer types, supporting RAD101’s broad diagnostic applicability. The study also suggested that PET-MRI imaging with RAD101 may serve as a non-invasive predictor of overall survival, warranting larger trials to confirm this prognostic potential.

The possibility that RAD101 PET-MRI could provide prognostic information, in addition to diagnostic accuracy, offers an added clinical benefit. If confirmed, this capability would help clinicians not only detect recurrent disease but also stratify patients by risk to tailor treatment intensity and follow-up schedules. This combination of diagnostic and prognostic utility strengthens the case for advancing RAD101 into Phase 3 and highlights its significance in managing brain metastases.